High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: Is it feasible?

T. De Pas, F. De Braud, L. Orlando, F. Nolè, E. Munzone, M. G. Zampino, N. Fazio, M. S. Aapro, A. Goldhirsch

Research output: Contribution to journalArticlepeer-review


Background: Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship. We evaluated the feasibility and toxicity of a high-dose IFO-plus-ADM combination. Patients and methods: Fourteen patients with advanced disease and nine patients in adjuvant setting received IFO 12.5 g/m2 in 120-hour continuous infusion with Mesna uroprotection and ADM 20 mg/m2 on days 1-3 and G-CSF every three weeks. Results: Twenty-three patients received 89 chemotherapy cycles (70 cycles at full dose). Seventeen patients received the planned treatment, and nine patients required dose reductions. We observed grade 3-4 neutropenia in 52 cycles (59%)/20 patients; grade 3-4 thrombocytopenia in 16 cycles (18%)/nine patients; grade 3-4 anaemia in 24 cycles (27%)/11 patients. Eight patients experienced febrile neutropenia and six patients required blood transfusions. Conclusions: While feasible, this regimen showed heavy toxicity. Nevertheless, 74% of the patients were able to complete the planned treatment. Adjustment of the schedule of IFO continuous infusion to improve this combination is currently under investigation.

Original languageEnglish
Pages (from-to)917-919
Number of pages3
JournalAnnals of Oncology
Issue number8
Publication statusPublished - Aug 1998


  • Doxorubicin
  • High-dose ifosfamide
  • Soft tissue sarcomas

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: Is it feasible?'. Together they form a unique fingerprint.

Cite this